Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 303 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: Forest Laboratories Clear all

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Memantine; Drug
Lead sponsor: Phoenix Neurological Associates, LTD; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Complicated Urinary Tract Infection, Complicated Intra-abdominal Infection
Interventions: Ceftazidime - Avibactam ( CAZ-AVI), Best Available Therapy, Metronidazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Shreveport, Louisiana • Lima, Ohio

Conditions: Memory Impairment
Interventions: Vilazodone, Placebo, Hydrocortisone; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Major Depressive Disorder
Interventions: Levomilnacipran ER, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 23
States / cities: Dothan, Alabama • Highlands Ranch, Colorado • Boca Raton, Florida + 18 more

Conditions: Atrial Fibrillation
Interventions: Azimilide Dihydrochloride, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 88
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 79 more

Conditions: Hypertension
Interventions: Metoprolol, Nebivolol; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Pharmacokinetic
Interventions: Cebranopadol 200 μg tablet; Drug
Lead sponsor: Tris Pharma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Major Depressive Disorder
Interventions: Escitalopram; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 18
States / cities: Phoenix, Arizona • Boulder, Colorado • Denver, Colorado + 15 more

Conditions: Back Pain
Interventions: Savella; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: Hypertension, Pure Autonomic Failure, Multiple System Atrophy
Interventions: Placebo, Nebivolol 5 mg, metoprolol tartrate 50 mg, Sildenafil25 mg; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Binge Eating Disorder
Interventions: acamprosate, placebo; Drug · Other
Lead sponsor: Lindner Center of HOPE; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Mason, Ohio

Conditions: Type 2 Diabetes Mellitus
Interventions: PHX1149T, Placebo; Drug
Lead sponsor: Phenomix; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 13
States / cities: Norwalk, California • Orange, California • Santa Ana, California + 10 more

Conditions: Fibromyalgia, Neurocognition
Interventions: Milnacipran, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: PTSD
Interventions: Escitalopram; Drug
Lead sponsor: VA Nebraska Western Iowa Health Care System; Federal
Eligibility: 19 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Peripheral Artery Disease, Hypertension
Interventions: nebivolol, Metoprolol succinate; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension
Interventions: Metoprolol succinate, Nebivolol, Non-invasive measurement of Cardiac Output (CO), Endothelial cell collection, Microvascular perfusion assessment using Definity; Drug · Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Bipolar Depression
Interventions: cariprazine, placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 26
States / cities: Encino, California • Garden Grove, California • National City, California + 23 more

Conditions: Separation Anxiety Disorder
Interventions: Vilazodone, Placebo; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension
Interventions: Nebivolol; Drug
Lead sponsor: Mercy Research; Other
Eligibility: 18 Years to 90 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Proctitis, Ulcerative
Interventions: MAX-002, Placebo, Canasa®; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 22
States / cities: Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 19 more

Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions: EUR-1008 (APT-1008), Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 7 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Tyler, Texas

Conditions: Pneumonia, Bacterial, Community-acquired
Interventions: Ceftaroline, Levofloxacin; Drug
Lead sponsor: Gary E. Stein, Pharm.D.; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Lansing, Michigan

Conditions: Methamphetamine Dependence, Treatment Seeking
Interventions: Acamprosate, placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Exercise-Induced Asthma
Interventions: Oglemilast, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 2
States / cities: Los Angeles, California • North Dartmouth, Massachusetts

Search by objective public record fields.

Memantine Therapy in Amyotrophic Lateral Sclerosis

Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens

Vilazodone for Corticosteroid-Induced Memory Impairment

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

Efficacy and Safety of Azimilide in the Prophylactic Treatment of Patients With Atrial Fibrillation.

Nebivolol Versus Metoprolol: Comparative Effects on Fatigue and Quality of Life

A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol

Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder

Pain Assessment and Quality of Life in Back Pain Patients: Role of Milnacipran

Nebivolol in the Supine Hypertension of Autonomic Failure

Acamprosate in the Treatment of Binge-Eating Disorder

Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus

Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial

Effects of Escitalopram on Autonomic Reactivity in Post Traumatic Stress Disorder

Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure

Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients

Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression

Vilazodone for Separation Anxiety Disorder

Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function

Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis

Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia

A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction

Study of Oglemilast for the Prevention of Asthma.